Table 2 Clinical characteristics and laboratory findings of patients from Cohort 2
From: Platelet activation in critically ill COVID-19 patients
Characteristics | Healthy controls | All patients | Disease severity | p value | ||
|---|---|---|---|---|---|---|
N = 13 | N = 32 | Mild-to-moderate | Severe | Critical | ||
N = 11 | N = 10 | N = 11 | ||||
Age, median (IQR), year | 59.2 (45.2, 60.0) | 55.6 (51.2, 64.8) | 55.9 (44.7–65.1) | 53.5 (48.02–61) | 60.2 (54.8–71.65) | 0.23 |
Male, no. (%) | 10 (77) | 24 (75) | 8 (72.7) | 9 (90) | 7 (63.6) | 0.37 |
Median interval from first symptoms on admission (IQR), days | – | 10 (9–11) | 9 (9–11) | 10.5 (10–12) | 9 (8–11) | 0.06 |
Coexisting disorder, no. (%) | ||||||
Any | 0 (0) | 14 (44) | 2 (18) | 3 (30) | 9 (82) | 0.006 |
COPD | 0 (0) | 1 (3) | 0 (0) | 0 (0) | 1 (9) | 0.37 |
Diabetes | 0 (0) | 5 (16) | 0 (0) | 1 (10) | 4 (36) | 0.053 |
Hypertension | 0 (0) | 10 (31) | 2 (18) | 2 (20) | 6 (55) | 0.12 |
Cardiovascular disease | 0 (0) | 3 (9) | 0 (0) | 0 (0) | 3 (27) | 0.042 |
Cancer or hemopathy | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | – |
Chronic renal disease | 0 (0) | 1 (3) | 0 (0) | 0 (0) | 1 (9) | 0.37 |
Overweight | 0 (0) | 2 (6) | 1 (9) | 1 (10) | 0 (0) | 0.5 |
Fever on admission | ||||||
Median temperature (IQR), °C | – | 38.9 (38.5–39.4) | 38.8 (38.2–39.5) | 38.6 (38.5–39.7) | 39.0 (38.5–39.4) | – |
Symptoms on admission (%) | ||||||
Fever | – | 32 (100) | 11 (100) | 10 (100) | 11 (100) | |
Dyspnea | – | 32 (100) | 11 (100) | 10 (100) | 11 (100) | |
Cough | – | 31 (97) | 10 (91) | 10 (100) | 11 (100) | 0.37 |
Fatigue | – | 31 (97) | 10 (91) | 10 (100) | 11 (100) | 0.37 |
Myalgia | – | 20 (63) | 8 (73) | 8 (10) | 4 (36) | 0.082 |
Diarrhea | – | 11 (34) | 4 (36) | 5 (50) | 1 (9) | 0.091 |
Median oxygen requirement (IQR, L/min) | ||||||
Clinical outcomes, no. (%) | ||||||
Thrombotic events | – | 3 (9) | 0 (0) | 1 (10) | 2 (18) | 0.34 |
Clinical worsening requiring MV | – | – | 0 (0) | 5 (50) | – | – |
Death | – | 5 (15.6) | 0 (0) | 0 (0) | 5 (45.5) | < 0.001 |
Laboratory findings on admission | ||||||
Leukocytes (IQR), × 109/L | – | 6.7 (4.31–8.82) | 4.71 (3.78–5.68) | 7.78 (6.46–8.43) | 9.38 (5.48–10.49) | 0.038 |
Neutrophils (IQR), x 109/L | – | 5.08 (3.12–7.37) | 3.25 (2.07–3.44) | 5.81 (4.74–6.36) | 7.69 (4.32–9.13) | 0.022 |
Lymphocytes (IQR), × 109/L | – | 0.84 (0.56–1.13) | 1.00 (0.84–1.40) | 0.88 (0.57–1.12) | 0.65 (0.45–0.84) | 0.031 |
Monocytes (IQR), × 109/L | – | 0.41 (0.23–0.52) | 0.40 (0.26–0.52) | 0.42 (0.27–0.51) | 0.33 (0.12–1.05) | 0.95 |
Platelets (IQR), × 109/L | – | 249 (159–298) | 166 (112–251) | 229 (170–282) | 313 (199–352) | 0.007 |
CRP (IQR), mg/L | 0.7 (0.0–0.8) | 118 (55–242) | 30 (14–76) | 169 (136–249) | 159 (109–308) | < 0.001 |
Lactate dehydrogenase (IQR), U/L | 169 (155–224) | 424 (346–574) | 262 (196–454) | 411 (396–623) | 504 (426–614) | 0.1 |